Dr. Sy Pretorius has been appointed chief scientific officer at PAREXEL, in addition to his current role as the company's corporate vice president and worldwide head of Early Phase.
Dr. Pretorius will lead innovation efforts for clinical research methodologies and help further integrate the company’s drug development services. He will focus on clinical trial modeling and simulations, adaptive trial designs, and will lead the company's study optimization services by aligning its scientific and therapeutic expertise to provide guidance to customers in clinical study design.
Dr. Pretorius has been with PAREXEL for 18 years, holding positions of increasing responsibility, most recently as head of Early Phase services. He will continue to lead global Phase I and IIa services, which spans three continents, as well as its global Proof of Concept division.
"Customers are increasingly seeking a full spectrum of integrated clinical research services from a single provider to make drug development more efficient," said Mark A. Goldberg, M.D., president and chief operating officer, PAREXEL. "To help us meet these requirements, we have not only recently added new senior leadership to our ranks, but we have expanded the role of one of our current executives. Sy Pretorius has enjoyed a long and distinguished career at the Company, and applying his expertise more broadly will benefit customers and PAREXEL alike."